LuciRegor — Regorafenib 40 mg, 28 pcs, Lucius

LuciRegor — Regorafenib Tablets 40 mg, 28 Tablets

Product code: 499

7152₴ 7778₴ -8% On order · from 10 days

Analogues

LuciRegor Regonat Stivarga
1
Active ingredient
Dosage form Tablets
Tablets per pack 28

LuciRegor is a potent multi-targeted antineoplastic agent belonging to the protein kinase inhibitor class, indicated for the treatment of metastatic colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma. The active pharmaceutical ingredient is regorafenib at a strength of 40 mg supplied as film-coated oral tablets (Regorafenib Tablets 40 mg). The product is developed and manufactured by Lucius Pharmaceuticals.

Regorafenib is an oral multi-kinase inhibitor targeting angiogenic kinases (VEGFR 1, 2, 3, TIE2), stromal factors (PDGFR-beta, FGFR), and oncogenic kinases (KIT, RET, RAF/BRAF). Through this broad spectrum of activity, regorafenib inhibits tumor angiogenesis, stromal growth, and cancer cell proliferation. Regorafenib is administered as second- or subsequent-line therapy following disease progression on standard regimens.

Supplied in a package containing 28 tablets of 40 mg. Intended exclusively for oral administration under the strict supervision of an oncologist.

Key Clinical Features and Advantages of LuciRegor 40 mg:

  • ✅ Multi-Targeted Action: Potent suppression of angiogenesis, tumor microenvironment, and cellular proliferation.
  • ✅ Broad Indication Spectrum: Proven efficacy in colorectal cancer, GIST, and liver cancer.
  • ✅ Oral Dosing Form: Convenient tablet administration for outpatient treatment settings.
  • ✅ Overcoming Resistance: Effective in patients progressing on prior lines of therapy.
  • ✅ Lucius Pharmaceuticals Standards: High-quality, accessible generic alternative to the originator product (Stivarga).

LuciRegor is supplied as film-coated tablets for oral administration.

Qualitative and Quantitative Composition per Tablet:

  • Active Ingredient: Regorafenib (as regorafenib monohydrate) — 40 mg.
  • Excipients: Microcrystalline cellulose, croscarmellose sodium, magnesium stearate, povidone, colloidal anhydrous silica. Coating: hypromellose, macrogol, titanium dioxide, iron oxide red.

Packaging and Presentation: Film-coated tablets, 40 mg strength. Each package contains 28 tablets along with prescribing information. Labeled with LuciRegor (Regorafenib Tablets 40 mg) and Lucius Pharmaceuticals corporate graphics.

Pharmacodynamics:
Regorafenib is an oral multi-protein kinase inhibitor. It blocks angiogenic receptors (VEGFR1, -2, -3, TIE2), growth factor receptors (PDGFR-beta, FGFR), and mutant oncogenic kinases (KIT, RET, RAF, BRAF, V600E). Inhibition of these targets results in decreased tumor vessel growth, blockade of tumor cell survival signaling pathways, and reduction of metastatic potential.

Pharmacokinetics:

  • Absorption: Following oral administration, peak plasma concentrations (Tmax) are achieved within 3 to 4 hours. Administration with a high-fat meal increases systemic exposure (recommended to be taken following a low-fat light meal).
  • Distribution: Human plasma protein binding of regorafenib is 99.5%.
  • Metabolism: Metabolized in the liver primarily via CYP3A4 and uridine diphosphate-glucuronosyltransferase (UGT1A9) to form two major active metabolites.
  • Elimination: Excreted predominantly via feces (approx. 71% as metabolites) and renally (approx. 19%). Terminal elimination half-life (T1/2) of the parent drug is approximately 20 to 28 hours.

LuciRegor is indicated in adult patients for:

  • Metastatic Colorectal Cancer (mCRC): Treatment of patients with mCRC who have been previously treated with available standard therapies (including fluoropyrimidine-based chemotherapy, oxaliplatin, and irinotecan, anti-VEGF therapy, and, if RAS wild-type, anti-EGFR therapy).
  • Gastrointestinal Stromal Tumors (GIST): Treatment of patients with advanced and/or metastatic GIST whose disease has progressed on or who have been intolerant to prior treatment with imatinib and sunitinib.
  • Hepatocellular Carcinoma (HCC): Treatment of patients with advanced HCC who have been previously treated with sorafenib.

LuciRegor is administered orally once daily for 3 consecutive weeks followed by 1 week off treatment (a 28-day treatment cycle).

Dosing Regimen:
The recommended standard dose is 160 mg (four 40 mg tablets) once daily for 21 consecutive days followed by 7 days off treatment.

Administration Guidelines:
Tablets should be taken at the same time each day following a low-fat meal (containing less than 30% fat) with water. Swallow tablets whole; do not break, crush, or dissolve.

Administration of LuciRegor is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to regorafenib or any excipient.
  • Pregnancy and Lactation: Strictly contraindicated in pregnant or breastfeeding women.
  • Pediatric Population: Safety and efficacy in patients under 18 years have not been established.
  • Severe Hepatic Impairment: Pronounced liver dysfunction (Child-Pugh Class C).

Regorafenib is metabolized by CYP3A4 and UGT1A9 enzymes:

  • Strong CYP3A4 Inducers (rifampicin, phenytoin, carbamazepine, phenobarbital, St. John's Wort): Significantly decrease regorafenib plasma concentrations and reduce efficacy. Avoid concurrent use.
  • Strong CYP3A4 Inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice): May increase active drug plasma concentrations.
  • BCRP and P-gp Substrates: Regorafenib may affect transporter systems, warranting caution when co-administered with sensitive substrates.

Pregnancy:
LuciRegor is contraindicated during pregnancy. Based on its mechanism of action, regorafenib may cause severe developmental defects and embryotoxicity. Females of reproductive potential and male partners must utilize effective contraception during treatment and for at least 2 weeks following the final dose.

Lactation:
Excretion of regorafenib into human breast milk is unstudied, though high risks to the infant are anticipated. Breastfeeding must be discontinued during treatment.

The most frequent and clinically significant adverse reactions include:

  • Dermatologic Reactions (Very Common): Palmar-plantar erythrodysesthesia (hand-foot syndrome), rash, peeling, alopecia.
  • Gastrointestinal Tract: Diarrhea, stomatitis, nausea, vomiting, abdominal pain, decreased appetite.
  • Cardiovascular System: Arterial hypertension (regular blood pressure monitoring required).
  • General Disorders: Fatigue, asthenia, weight loss, pyrexia, dysphonia (hoarseness).
  • Laboratory Abnormalities: Elevations in liver transaminases (ALT, AST), bilirubin, thrombocytopenia, neutropenia.

Symptoms:
Symptoms of regorafenib overdose include exacerbation of dermatologic adverse reactions (hand-foot syndrome), severe diarrhea, stomatitis, and elevated liver function test parameters.

Treatment:
No specific antidote exists. In case of overdose, interrupt treatment, and initiate supportive and symptomatic care under strict medical monitoring.

Storage Requirements for LuciRegor 40 mg:

  • 🌡️ Temperature Range: Store in original packaging in a dry place protected from light at temperatures below 30 °C.
  • 👶 Safety Precautions: Keep strictly out of reach of children (cytotoxic antineoplastic agent).
  • ⏳ Shelf Life: Stated on carton and blister pack. Don't use past expiration date. Prescription-only oncology medicine.

To verify authenticity of genuine LuciRegor 40 mg manufactured by Lucius Pharmaceuticals, inspect the following security and visual features:

  • ✅ Security Hologram & Scratch Code: Outer carton features an official Lucius Pharmaceuticals anti-counterfeit holographic seal with a scratch-off verification code for online validation via the manufacturer's official portal.
  • ✅ Corporate Branding: High-resolution printing displaying Lucius Pharmaceuticals graphics, Regorafenib Tablets 40 mg, and 28 Tablets count.
  • ✅ Factory Markings: Clearly printed Batch No., Mfg. Date, and Exp. Date matching across outer packaging and internal blister packs.
  • ✅ Prescribing Information: Includes an official product leaflet inside the outer carton.
On order · from 10 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 14.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00